Osler

A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145

Osler [NCT01439880]

Description: The primary clinical hypothesis is that long-term exposure of AMG 145 will be safe and well tolerated in subjects with hypercholesterolemia.

Drug: AMG 145 and standard of care; Other: Standard of care

Primary Investigator: Bailey

Drug/Device Information
AMG 145 (fully human monoclonal immunoglobulin (Ig) G2 SQ
Binds to PCSK9 and prevents down regulation of LDLR which decreases LDL.
Open label extension study
Amgen
Major Inclusion and Exclusion
Completed the Laplace (Timi 57) trial